Interestingly, the phosphorylation of all the analyzed CRLF2 downstream effectors was better exploited by the SRC/ABL inhibitor dasatinib compared to the specific JAK1/2 inhibitor, ruxolitinib, currently tested in phase II clinical study to treat Ph-like ALL patients bearing CRLF2 alterations. The gene discussed is SRC; the disease is acute lymphoblastic leukemia.